|
| 36709390 | Sequencing of genes of drug response in tumor DNA and implications for precision medicine in cancer patients. | Pharmacogenomics J | 2023 |
| 36652552 | NFE2L2 Mutations Enhance Radioresistance in Head and Neck Cancer by Modulating Intratumoral Myeloid Cells. | Cancer Res | 2023 |
| 36709390 | Sequencing of genes of drug response in tumor DNA and implications for precision medicine in cancer patients. | Pharmacogenomics J | 2023 |
| 36694401 | A risk prediction model for head and neck cancers incorporating lifestyle factors, HPV serology and genetic markers. | Int J Cancer | 2023 |
| 37370794 | Unsupervised Hierarchical Clustering of Head and Neck Cancer Patients by Pre-Treatment Plasma Metabolomics Creates Prognostic Metabolic Subtypes. | Cancers (Basel) | 2023 |
| 37182801 | A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer. | Ann Oncol | 2023 |
| 37233991 | Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non-Small Cell Lung Cancer: The Piedmont Study. | Clin Cancer Res | 2023 |
| 37486534 | HN-CLEAR: Head and Neck Consensus Language for Ease and Reproducibility, a Multidisciplinary Consensus Mechanism for Head and Neck Pathology. | Head Neck Pathol | 2023 |
| 36979627 | Racial Differences in Androgen Receptor (AR) and AR Splice Variants (AR-SVs) Expression in Treatment-Naïve Androgen-Dependent Prostate Cancer. | Biomedicines | 2023 |
| 37486534 | HN-CLEAR: Head and Neck Consensus Language for Ease and Reproducibility, a Multidisciplinary Consensus Mechanism for Head and Neck Pathology. | Head Neck Pathol | 2023 |
| 37182801 | A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer. | Ann Oncol | 2023 |
| 36979627 | Racial Differences in Androgen Receptor (AR) and AR Splice Variants (AR-SVs) Expression in Treatment-Naïve Androgen-Dependent Prostate Cancer. | Biomedicines | 2023 |
| 37370794 | Unsupervised Hierarchical Clustering of Head and Neck Cancer Patients by Pre-Treatment Plasma Metabolomics Creates Prognostic Metabolic Subtypes. | Cancers (Basel) | 2023 |
| 37233991 | Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non-Small Cell Lung Cancer: The Piedmont Study. | Clin Cancer Res | 2023 |
| 36694401 | A risk prediction model for head and neck cancers incorporating lifestyle factors, HPV serology and genetic markers. | Int J Cancer | 2023 |
| 36652552 | NFE2L2 Mutations Enhance Radioresistance in Head and Neck Cancer by Modulating Intratumoral Myeloid Cells. | Cancer Res | 2023 |
| 35263677 | Mature follow up of induction chemotherapy with carboplatin, nab-paclitaxel, cetuximab in head and neck squamous cell carcinoma. | Oral Oncol | 2022 |
| 35775614 | Response to immune checkpoint blockade improved in pre-clinical model of breast cancer after bariatric surgery. | Elife | 2022 |
| 35446600 | For Head and Neck Cancer, It Is Still Cisplatin, But How Much, How Often, and How Tolerable? New Randomized Phase III Data For the Adjuvant Setting. | J Clin Oncol | 2022 |
| 35577980 | TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice. | Oncogene | 2022 |
| 36148399 | Tumor Cell Extrinsic Synaptogyrin 3 Expression as a Diagnostic and Prognostic Biomarker in Head and Neck Cancer. | Cancer Res Commun | 2022 |
| 36002660 | Correction: TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice. | Oncogene | 2022 |
| 35494251 | Integrative genomic analysis reveals low T-cell infiltration as the primary feature of tobacco use in HPV-positive oropharyngeal cancer. | iScience | 2022 |
| 36147910 | Mesenchymal gene expression subtyping analysis for early-stage human papillomavirus-negative head and neck squamous cell carcinoma reveals prognostic and predictive applications. | Front Oncol | 2022 |
| 36194164 | A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck. | Clin Cancer Res | 2022 |
| 35924981 | DiNAMIC.Duo: detecting somatic DNA copy number differences without a normal reference. | Bioinformatics | 2022 |
| 36420184 | Evolutionary Action Score of <i>TP53</i> Analysis in Pathologically High-Risk Human Papillomavirus-Negative Head and Neck Cancer From a Phase 2 Clinical Trial: NRG Oncology Radiation Therapy Oncology Group 0234. | Adv Radiat Oncol | 2022 |
| 35319799 | The pancreatic cancer immune tumor microenvironment is negatively remodeled by gemcitabine while TGF-β receptor plus dual checkpoint inhibition maintains antitumor immune cells. | Mol Carcinog | 2022 |
| 35064062 | Characterization of Epigenomic Alterations in HPV16+ Head and Neck Squamous Cell Carcinomas. | Cancer Epidemiol Biomarkers Prev | 2022 |
| 35025619 | Mutant <i>PPM1D</i>- and <i>TP53</i>-Driven Hematopoiesis Populates the Hematopoietic Compartment in Response to Peptide Receptor Radionuclide Therapy. | JCO Precis Oncol | 2022 |
| 35263677 | Mature follow up of induction chemotherapy with carboplatin, nab-paclitaxel, cetuximab in head and neck squamous cell carcinoma. | Oral Oncol | 2022 |
| 35775614 | Response to immune checkpoint blockade improved in pre-clinical model of breast cancer after bariatric surgery. | Elife | 2022 |
| 35577980 | TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice. | Oncogene | 2022 |
| 35494251 | Integrative genomic analysis reveals low T-cell infiltration as the primary feature of tobacco use in HPV-positive oropharyngeal cancer. | iScience | 2022 |
| 35446600 | For Head and Neck Cancer, It Is Still Cisplatin, But How Much, How Often, and How Tolerable? New Randomized Phase III Data For the Adjuvant Setting. | J Clin Oncol | 2022 |
| 36420184 | Evolutionary Action Score of <i>TP53</i> Analysis in Pathologically High-Risk Human Papillomavirus-Negative Head and Neck Cancer From a Phase 2 Clinical Trial: NRG Oncology Radiation Therapy Oncology Group 0234. | Adv Radiat Oncol | 2022 |
| 36002660 | Correction: TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice. | Oncogene | 2022 |
| 36148399 | Tumor Cell Extrinsic Synaptogyrin 3 Expression as a Diagnostic and Prognostic Biomarker in Head and Neck Cancer. | Cancer Res Commun | 2022 |
| 36147910 | Mesenchymal gene expression subtyping analysis for early-stage human papillomavirus-negative head and neck squamous cell carcinoma reveals prognostic and predictive applications. | Front Oncol | 2022 |
| 35924981 | DiNAMIC.Duo: detecting somatic DNA copy number differences without a normal reference. | Bioinformatics | 2022 |
| 36194164 | A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck. | Clin Cancer Res | 2022 |
| 35319799 | The pancreatic cancer immune tumor microenvironment is negatively remodeled by gemcitabine while TGF-β receptor plus dual checkpoint inhibition maintains antitumor immune cells. | Mol Carcinog | 2022 |
| 35064062 | Characterization of Epigenomic Alterations in HPV16+ Head and Neck Squamous Cell Carcinomas. | Cancer Epidemiol Biomarkers Prev | 2022 |
| 35025619 | Mutant <i>PPM1D</i>- and <i>TP53</i>-Driven Hematopoiesis Populates the Hematopoietic Compartment in Response to Peptide Receptor Radionuclide Therapy. | JCO Precis Oncol | 2022 |
| 32828918 | Novel Use of Biphasic Cuirass Ventilation During Definitive Radiation Therapy: A Technical Report. | Pract Radiat Oncol | 2021 |
| 33971700 | The anatomy of COVID-19 comorbidity networks among hospitalized Korean patients. | Epidemiol Health | 2021 |
| 33694102 | Role of TGF-β in pancreatic ductal adenocarcinoma progression and PD-L1 expression. | Cell Oncol (Dordr) | 2021 |
| 33688646 | Systematic analysis of SARS-CoV-2 infection of an ACE2-negative human airway cell. | bioRxiv | 2021 |
| 34165221 | Outcomes of primary radiotherapy with or without chemotherapy for advanced oral cavity squamous cell carcinoma: Systematic review. | Head Neck | 2021 |
| 33626346 | CRTC1/MAML2 directs a PGC-1α-IGF-1 circuit that confers vulnerability to PPARγ inhibition. | Cell Rep | 2021 |